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INTRODUCTION
HER2 is overexpressed or amplified in 15% to 25% of breast 
cancers. Determination of HER2 tumor status offers clinically 
useful information. HER2 is composed of a cytoplasmic do-
main with tyrosine kinase activity, a transmembrane domain 
and an extracellular domain (ECD) [1,2]. The HER2 ECD may 
be cleaved and shed from the surface of breast cancer cells and 
serum HER2 levels can be detected by enzyme-linked immu-
nosorbent assays (ELISAs) without any significant cross-reac-
tivity with other members of the HER receptor family [1,3]. 
Many reports have associated increased serum HER2 concen-
tration with earlier disease recurrence and shortened overall 
survival (OS), decreased response to chemotherapy and hor-
monal therapy, and prediction of response to trastuzumab 
based treatments [1-4]. The association between tissue HER2 
status and serum HER2 is controversial, as some studies have 
identified a positive correlation, while others have not. The 
aims of our study were to assess 1) the correlation between se-
rum HER2 and clinicopathologic factors, 2) the effect of se-
rum HER2 on survival rate, and 3) the effect of changes in se-
rum HER2 levels between pre-adjuvant chemotherapy and 
post-adjuvant chemotherapy on survival rate.
METHODS
Patients and specimens
For this study, we included 200 patients with primary breast 
cancer who were treated at Kosin University Hospital between 
January 2005 and December 2006. This retrospective trial was 
conducted in patients with a histological diagnosis of stage I-
III breast cancer treated with conservative surgery or mastec-
tomy. Tumor staging followed the tumor-node-metastasis 
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Purpose: The aims of our study were to assess the correlation 
between serum HER2 and clinicopathologic factors, the effect of 
serum HER2 on survival rate, and the effect of changes in serum 
HER2 levels between pre- and post-adjuvant chemotherapy on 
survival rate. Methods: The study subjects, 200 women with 
breast cancer, were a subset of patients operated on between 
January 2005 and December 2006. We evaluated changes in 
serum HER2 levels between pre- and post-adjuvant chemother-
apy. Results: Being estrogen receptor (ER) negative was also 
correlated with high serum HER2 (p=0.017). The number of pa-
tients with changes in serum HER2 (>20% increased level dur-
ing the follow-up period) was correlated with advanced T-stage 
(p=0.010), advanced American Joint Committee on Cancer 
(AJCC) stage (p=0.015) and poor histologic grade (p=0.001). 
Univariate analysis for prognostic factors associated with dis-
ease-free survival (DFS) revealed that the difference in DFS be-
tween those with serum HER2 level <15 ng/mL and those with 
levels  ≥15 ng/mL was statistically significant (p=0.0129) and 
the changes in serum HER2 levels were also statistically signifi-
cant (p=0.001). Prognostic factors associated with overall sur-
vival revealed that the changes in serum HER2 levels between 
pre- and post-adjuvant chemotherapy were statistically signifi-
cant (p=0.0012). Conclusion: Serum HER2 level is associated 
with a more advanced degree of axillary lymph node involve-
ment and associated with ER negativity. And Changes in serum 
HER2 levels are associated with more advanced AJCC staging 
and histologic tumor grade. There are significant associations 
between serum HER2 level, changes in serum HER2 levels and 
5-year DFS. 
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(TNM)-American Joint Committee on Cancer (AJCC) classi-
fication and the p-TNM was obtained after classical patholog-
ical examination. Patients with metastatic disease and with 
other previous tumors were excluded from this study. Immu-
nohistochemical screening for estrogen receptors (ER), pro-
gesterone receptors (PR), and HER2 status was performed on 
formalin-fixed paraffin embedded tissue blocks of the prima-
ry tumor in the Pathology Department of the Kosin Universi-
ty Hospital. Recorded clinical and pathological features for 
each patient include age, histologic grade, Ki-67, ER, and PR 
status, AJCC stage, surgical treatment and medical adjuvant 
therapy. Follow-up, including a clinical examination (every 6 
months for the first 2 years, every 1 year for the next 3 years), 
mammography, bone scan and chest X-ray were carried out 
in all patients. Recurrence was defined as the first document-
ed evidence of new disease manifestation in the locoregional 
area, in the contralateral breast, in distant sites, or in a combi-
nation of these. The study was reviewed and approved by the 
Institutional Review Board (No. 11-104) and informed con-
sent was obtained from all patients.
Serum HER2 assays
The ADVIA Centaur HER2 assay
TM (Siemens, Tarrytown, 
USA), which is available as both a manual microtiter plate and 
as an automated platform, was approved by the U.S. Food and 
Drug Administration (FDA) in 2000. It uses two monoclonal 
antibodies against two independent epitopes of the serum 
HER2 protein (NG-3 and TA-1), The assay is calibrated using 
dilutions of serum HER2 control. The ECD calibrator is a re-
combinant protein secreted by HER2 ECD-transfected mouse 
NIH 3T3 cells. Quality control was ensured by assaying the 
two levels of control sera supplied with the kit in each series. 
Mean standard deviation (SD) and coefficient of variation 
(CV) for the controls were 15.7 vs. 0.75 ng/mL (CV, 4.5%) and 
112.9 vs. 4.99 ng/mL (CV, 4.4%), respectively. This automated 
assay for serum HER2 was demonstrated to be accurate, pre-
cise, resistant to interferences and reliable for longitudinal 
monitoring; the upper limit of normal was defined as 15 ng/
mL [4,5]. Receiver operating curve (ROC) analysis was per-
formed to determine the optimal serum HER2 cutoff level. 
From that ROC analysis, a significant serum HER2 decline 
was defined as a decrease >20% at the follow-up visit (Figure 
1). This definition of a significant change was similar to that 
derived from the FDA cleared cutoff value for non trastuzum-
ab therapies. We measured serum HER2 levels between pre-
adjuvant chemotherapy and post-adjuvant chemotherapy and 
then analysed the percentage of changes of serum HER2 lev-
els (<20% vs. ≥20%). Further data analysis was performed 
by comparing the group of patients who achieved this signifi-
cant decline in serum HER2 level (>20%) with patients who 
did not achieve this decline in serum HER2. 
Other histopathological features assays
Histopathological features such as hormone receptor status 
and HER2 status on immunohistochemistry were all analyzed 
at the Institute of Pathology at the Kosin University Hospital. 
Expressions of p53, ER, Ki-67, and HER2 were determined 
immunohistochemically on paraffin sections using antibodies 
against ER, Ki-67, HER2, and p53. Histologic grading was 
performed using the criteria of Bloom and Richardson [1,3]. 
Lymphatic vascular invasion (LVI) was defined as the pres-
ence of tumor emboli in peritumoral lymphatic spaces, capil-
laries or postcapillary venules. ER status and PR status were 
taken as positive if more than 10% of tumor cells showed stain-
ing. An immunohistochemical score of 3+ or fluorescence in 
situ hybridization (FISH)+ for HER2 was accepted as HER2 
positivity. 
Statistical analysis
Disease-free survival (DFS) was defined as the time from 
surgery to first appearance of disease or death from any cause. 
Survival curves were estimated using the Kaplan-Meier method. 
Statistical tests were performed using the SPSS version 12.0 
statistical software package for Windows (SPSS Inc., Chicago, 
USA). The survival function was calculated from the time of 
the onset of disease to the occurrence of death. Survival data 
were censored on December 31, 2009, which was the date on 
which the survival data were correlated with the death registry 
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Figure 1. This grape illustrates the area under the receiver operating 
characteristic (ROC) curve for changes in serum HER2 levels and pa-
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for the last time or 5 years after the onset of the disease. Ka-
plan-Meier estimates are presented for the survival function, 
and differences in survival were analyzed using the log-rank 
test. Associations between specific histopathological and clin- 
ical survival estimates and curves were established using the 
Kaplan-Meier method and differences in observed survival 
distribution among patient subgroups were tested with a two-
sided log-rank test. All survival rates are presented with their 
standard errors. We used Pearson’s correlation to determine 
the association of pairs of explanatory variables and differenc-
es in qualitative variables were evaluated by a chi-square test, 
where necessary. All p-values were two-sided and a p-value of 
less than 0.05 was considered to indicate a statistically signifi-
cant difference.
RESULTS
The main clinicopathological characteristics of the patients in 
our series are summarized in Table 1. Mean age was 50 years. 
T1 stage was reported in 114 patients (57.0%). N0 stage was 
reported in 94 patients (47.0%). All patients underwent sur-
gery: conservative surgery was carried out in 159 patients 
(79.6%) and mastectomy in 41 patients (20.4%). Radiotherapy 
was delivered to 169 patients (84.5%). Adjuvant chemotherapy 
was administered to 183 patients (91.7%): 24 patients (13.1%) 
received combination chemotherapy with cyclophosphamide, 
methotrexate and fluorouracil, 129 patients (70.5%) anthracy-
cline-based therapy, 3 patients (1.4%) taxane-based therapy 
and 30 patients (15.0%) anthracycline- and taxane-based regi-
mens. Endocrine therapy was administered to 144 of 200 pa-
tients (72.0%). With a cutoff value of 15 ng/mL, 14 of the 200 
patients (7.0%) had serum HER2 levels ≥15 ng/mL (high levels) 
and 186 patients (93.0%) had serum HER2 levels <15 ng/mL 
(low levels). Cancer tissue HER2 status was positive (3+ by 
immunohistochemistry [IHC] or 2+ by IHC with FISH am-
plification) in 76 patients (38.0%) and negative in 124 patients 
(62.1%). The bivariate distributions of patients with tissue HER2 
status and baseline serum HER2 levels are shown in Table 2. 
We observed high serum HER2 levels in 7.8% (6 of 76) of pa-
tients with tissue HER2-positive status versus only 6.4% (8 of 
124) of patients with tissue HER2-negative status. There was 
no significant association between high serum HER2 levels and 
tissue HER2 status (p=0.451). But high serum HER2 levels 
were significantly associated with lymph node involvement (p= 
0.037) and ER negativity (p=0.017) (Table 3). No significant 
relationship was found between serum HER2 levels and other 
variables, such as age, tumor size, PR, and p53. We observed 
serum HER2 with more than 20% increased modulation in 
54.0% (108 of 200) versus only 9.5% (19 of 200) of patients with 
Table 1. Patients and tumor characteristics 
Characteristics Mean (range) No. (%)
Age (yr) 50.37 (25.9-78.9)
pT    
   T1 114 (57.0)
   T2 54 (27.0)
   T3 32 (16.0)
pN
   N0 94 (47.0)
   N1 37 (18.5)
   N2 47 (23.5)
   N3 22 (11.0)
AJCC Stage
   I 78 (39.0)
   IIA 39 (19.5)
   IIB 18 (9.0)
   IIIA 8 (4.0)
   IIIB 35 (17.5)
   IIIC 22 (11.0)
ER status
   Negative 56 (28.0)
   Positive 144 (72.0)
PR status
   Negative 58 (29.0)
   Positive 142 (71.0)
HER2 status
   Negative 124 (62.0)
   Positive 76 (38.0)
Histologic grade
   G1 89 (44.5)
   G2 62 (31.0)
   G3 49 (24.5)
p53 status
   Negative 116 (58.0)
   Positive 84 (42.0)
Ki-67
   Negative 61 (30.5)
   Positive 139 (69.5)
Serum HER2*
   High level 14 (7.0)
   Low level 186 (93.0)
AJCC=American Joint Committee on Cancer; ER=estrogen receptor; PR= 
progesterone receptor.
*High level, serum HER2 ≥15 ng/mL; Low level, serum HER2 <15 ng/mL.
Table 2. Association between tissue HER2 status and serum HER2 
levels
Tissue HER2 status*
Positive Negative Total p-value
Serum HER2  0.451
High ≥15 ng/mL   6   8   14
Low <15 ng/mL 70 116 186
Total 76 124 128
*3+ by immunohistochemical staining (IHC) or 2+ by IHC with fluorescent in 
situ hybridization.74  DongWonRyu,etal.
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more than 20% decreased modulation. Serum HER2 with 
more than 20% increased modulation was significantly asso-
ciated with advanced AJCC stage (Table 4). At a median fol-
low-up of 3.14 years (range, 2.85-3.38 years). Univariate anal-
ysis for prognostic factors associated with DFS revealed that 
the difference in factors between serum HER2 level <15 ng/
mL and ≥15 ng/mL was statistically significant (p=0.012) 
(Figure 2). Changes in serum HER2 levels were also signifi-
cant (p=0.001) (Figure 3). Differences in serum HER2 were 
significantly different between tumor groups (T1, T2, T3, and 
T4) (p=0.002) and between lymph node stage groups (N0, N1, 
N2, and N3) (p<0.001) (Table 5). Univariate analysis for prog-
nostic factors associated with OS revealed that the changes in 
serum HER2 level were significant (p=0.001). Lymph node 
stage groups (N0, N1, N2, and N3) were also significant (p= 
0.006) (Table 6). 
DISCUSSION
HER2 is a 185 kDa protein composed of three domain; a 
cytoplasmic domain, a transmembrane domain and an ECD 
[1-3]. The ECD of HER2 can be cleaved from the surface of 
breast cancer cells by matrix metalloproteases and released 
into the serum, where it is detectable using an ELISA [4-6]. 
Before the FDA guideline were promulgated, a variety of dif-
ferent assays and cutoffs were used. These made it difficult to 
reach robust conclusions from the date derived. But the cur-
rently approved cutoff for an elevated serum HER2 is greater 
than 15 ng/mL, which results in a positive test in approximately 
Table 3. Relationship between serum HER2 levels and clinicopathologi-
cal variables
Characteristics 
Serum HER2
<15 ng/mL
No. (%)
Serum HER2
≥15 ng/mL
No. (%)
Total p-value
pT 0.149
   T1 103 (55.4) 11 (78.6) 114
   T2 51 (27.4) 3 (21.4) 54
   T3 32 (17.2) 0 (0) 32
pN 0.037
   N0 83 (44.6) 11 (78.6) 94
   N1 34 (18.3) 3 (21.4) 37
   N2 47 (25.3) 0 (0) 47
   N3 22 (11.8) 0 (0) 22
AJCC stage 0.153
   I 69 (37.1) 9 (64.3) 78
   IIA 35 (18.8) 4 (28.6) 39
   IIB 17 (9.1) 1 (7.1) 18
   IIIA 8 (4.3) 0 (0) 8
   IIIB 35 (18.8) 0 (0) 35
   IIIC 22 (11.8) 0 (0) 22
ER 0.017
   Negative 48 (25.8) 8 (57.1) 56
   Positive 138 (74.2) 6 (42.9) 144
PR 0.072
   Negative 51 (27.4) 7 (50.0) 58
   Positive 135 (72.6) 7 (50.0) 142
HER2 0.451
   Negative 116 (62.4) 8 (57.1) 124
   Positive 70 (37.6) 6 (42.9) 76
Histologic grade 0.161
   G1 86 (46.2) 3 (21.4) 89
   G2 55 (29.6) 7 (50.0) 62
   G3 45 (24.2) 4 (28.6) 49
p53 0.221
   Negative 106 (57.0) 10 (71.4) 116
   Positive 80 (43.0) 4 (28.6) 84
AJCC=American Joint Committee on Cancer; ER=estrogen receptor; PR= 
progesterone receptor.
Table 4. Relationship between the changes in serum HER2 levels and 
clinicopathological variables
Characteristics   
Serum HER2/neu level change
Total p-value ≤20% 
up
>20% 
up
≤20% 
down
>20% 
down
pT   0.010
   T1 20 (48.8) 60 (55.6) 18 (56.3) 16 (84.2) 114 (57.0)
   T2 14 (34.1) 24 (22.2) 13 (40.6) 3 (15.8) 54 (27.0)
   T3 7 (17.1) 24 (22.2) 1 (3.1) 0 (0) 32 (16.0)
pN   0.024
   N0 21 (51.2) 42 (38.9) 19 (59.4) 12 (63.2) 94 (47.0)
   N1 4 (9.8) 21 (19.4) 6 (31.6) 6 (31.6) 37 (18.5)
   N2 12 (29.3) 32 (29.6) 2 (6.3) 1 (5.3) 47 (23.5)
   N3 4 (9.8) 13 (12.0) 5 (15.6) 0 (0) 22 (11.0)
AJCC stage   0.015
   I 16 (39.0) 37 (34.3) 13 (40.6) 12 (63.2) 78 (63.2)
   IIA 5 (12.2) 20 (18.5) 9 (28.1) 5 (26.3) 39 (19.5)
   IIB 3 (7.3) 11 (10.2) 3 (9.4) 1 (5.3) 18 (9.0)
   IIIA 5 (12.2) 1 (0.9) 1 (3.1) 1 (5.3) 8 (4.0)
   IIIB 8 (19.5) 26 (24.1) 1 (3.1) 0 (0) 35 (17.5)
   IIIC 4 (9.8) 13 (12.0) 5 (15.6) 0 (0) 22 (11.0)
ER   0.186
   Negative 11 (26.8) 26 (24.1) 14 (43.8) 5 (26.3) 56 (28.0)
   Positive 30 (73.2) 82 (75.9) 18 (56.3) 14 (73.7) 144 (72.0)
PR   0.095
   Negative 14 (34.1) 24 (22.2) 14 (43.8) 6 (31.6) 58 (29.0)
   Positive 27 (65.9) 84 (77.8) 18 (56.3) 13 (68.4) 142 (71.0)
p53   0.358
   Negative 26 (63.4) 59 (54.6) 17 (53.1) 14 (73.7) 116 (58.0)
   Positive 15 (36.6) 49 (45.4) 15 (46.9) 5 (26.3) 84 (42.0)
Ki-67   0.152
   Negative 10 (24.4) 31 (28.7) 10 (31.1) 10 (52.6) 61 (30.5)
   Positive 31 (75.6) 77 (71.3) 22 (68.8) 9 (47.4) 139 (69.5)
Histologic grade <0.001
   I 12 (29.3) 64 (59.3) 4 (12.5) 9 (47.4) 89 (44.5)
   II 19 (46.3) 20 (18.5) 16 (50.0) 7 (36.8) 62 (31.0)
   III 10 (24.4) 24 (22.2) 12 (37.5) 3 (15.8) 49 (24.5)
Values represent number (%).
AJCC=American Joint Committee on Cancer; ER=estrogen receptor; PR= 
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5% of healthy controls [7-9]. So we also defied the 15 ng/mL 
upper limit of normal. Increased levels of serum HER2 (15 
ng/mL) can be detected in approximately 15% to 30% of un-
selected presurgical breast cancer samples and in up to 45% of 
patients with metastatic breast cancer, suggesting that serum 
HER2 levels may be reflective of a more aggressive tumor type 
[10-13]. According to our study, increased serum HER2 was 
detected in approximately 7%. A relatively low rate of increased 
serum HER2 may be attributable to variability in tissue metallo- 
proteinases (TMPs), which generate proteolytic cleavage of full 
length HER2. ECD production is increased by TMP activators 
and is decreased by TMP inhibitors in vitro. Increased levels of 
serum ECD have also been correlated with higher relapse rates, 
and patients in whom ECD levels exceed the upper limit of 
normal (ULN) for prolonged periods have been shown to have 
a poor prognosis [2,14]. Serum HER2 levels have been pro-
Figure 2. Kaplan-Meier estimates for disease-free survival according to 
serum HER2 levels.
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Figure 3. Kaplan-Meier estimates for disease-free survival according to 
changes in serum HER2 levels.
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Table 5. Univariate analysis for variable considered for DFS
Total No. (events) Survival rate (%) p-value
Serum HER2 (ng/mL) 0.012
  <15  186 (73) 60.75
  ≥15  14 (0) 100
Changes of serum HER2 level 0.001
  ≤20% up 41 (6) 85.37
  >20% up 108 (63) 41.67
  ≤20% down 32 (3) 90.63
  >20% down 19 (1) 94.75
pT 0.002
   T1 114 (40) 64.91
   T2 54 (8) 85.19
   T3 32 (25) 21.88
pN 0.001
   N0 94 (13) 86.17
   N1 37 (13) 64.86
   N2 47 (34) 27.66
   N3 22 (13) 40.91
AJCC stage 0.001
   I  78 (18) 76.92
   IIA 39 (9) 76.92
   IIB 18 (3) 83.33
   IIIA 8 (1) 87.50
   IIIB 35 (29) 17.14
   IIIC 22 (13) 40.91
ER 0.001
   Negative 56 (7) 87.50
   Positive 144 (66) 54.17
PR 0.001
   Negative 58 (6) 89.66
   Positive 142 (67) 52.82
HER2 0.208
   Negative 124 (47) 62.10
   Positive 76 (26) 65.79
p53 0.005
   Negative 116 (30) 74.14
   Positive 84 (43) 48.81
Ki-67 0.208
   Negative 61 (23) 62.30
   Positive 139 (50) 64.30
Histologic grade <0.001
   I 89 (63) 29.21
   II 62 (5) 91.94
   III 49 (5) 89.80
DFS=disease-free survival; AJCC=American Joint Committee on Cancer; 
ER=estrogen receptor; PR=progesterone receptor.76  DongWonRyu,etal.
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posed as a method of determining the HER2 status of breast 
cancers and potential eligibility for trastuzumab treatment 
[3,15]. Several studies demonstrate a decrease in serum HER2 
regardless of response, but there is a consensus that increasing 
serum HER2 levels indicates progressive disease. Most, but not 
all, studies reported that serum HER2 decreases to a greater 
degree among responders than non-responders. There have 
been efforts to establish algorithms to relate the magnitude of 
Table 6. Univariate analysis for variable considered for OS
Total No. (events) Survival rate (%) p-value
Serum HER2 (ng/mL) 0.163
  <15 186 (27) 85.48
  ≥15 14 (0) 100
Changes of serum HER2 level 0.001
  ≤20% up 41 (0) 100
  >20% up 108 (26) 75.93
  ≤20% down 32 (1) 96.88
  >20% down 19 (0) 100
pT 0.052
   T1 114 (11) 90.35
   T2 54 (7) 87.04
   T3 32 (9) 71.88
pN 0.006
   N0 94 (4) 95.74
   N1 37 (7) 81.08
   N2 47 (12) 74.47
   N3 22 (4) 81.82
AJCC stage 0.087
   I  78 (4) 94.87
   IIA 39 (5) 87.18
   IIB 18 (3) 83.33
  IIIA 8 (1) 87.50
   IIIB 35 (10) 71.43
   IIIC 22 (4) 81.82
ER 0.054
   Negative 56 (4) 92.86
   Positive 144 (23) 84.03
PR 0.008
   Negative 58 (3) 94.83
   Positive 142 (24) 83.10
HER2 0.288
   Negative 124 (19) 84.68
   Positive 76 (8) 89.47
p53 0.003
   Negative 116 (8) 93.10
   Positive 84 (19) 77.38
Ki-67 0.901
   Negative 61 (8) 86.89
   Positive 139 (19) 86.33
Histologic grade 0.001
   I 89 (22) 75.28
   II 62 (3) 95.16
   III 49 (2) 95.92
OS=overall survival; AJCC=American Joint Committee on Cancer; ER=estro-
gen receptor; PR=progesterone receptor. 
the decrease with the benefit from treatment. One study showed 
that those with a greater than 20% decrease in serum HER2 
have a greater benefit from trastuzumab-based therapy than 
those with a less than 20% decrease. Also, in our study, a signif-
icant serum HER2 decline was defined as a decrease >20% at 
the follow-up visit. This definition of a significant change was 
similar to that derived from the FDA cleared cutoff value for 
non-trastuzumab therapies [7-9]. Further data analysis was 
performed by comparing the group of patients who achieved 
this significant decline in serum HER2 level (>20%) with     
patients who did not achieve this decline in serum HER2. How-
ever, not all patients with HER2-positive breast cancer have 
elevated serum HER2 levels and, in a series of 55 patients, levels 
above the ULN were detected in one third of patients with 
HER2-negative disease [16-18]. Therefore, tissue-based methods 
such as IHC and FISH or chromogenic in situ hybridization 
should still be used to determine HER2 status, as these involve 
direct assessment of HER2 in the tumor [19,20]. According to 
our study, the sensitivity of serum HER2 is 7.8%. The variation 
in sensitivity may be attributable in part to the cutoffs and to 
the fact that, in some studies, it is unclear whether the serum 
was collected pre- or postoperatively. At 90-95%, specificity 
was better, but it suggests that some women with HER2 nega-
tive tumors secrete detectable amounts of serum HER2. Accord-
ing to our study, the specificity was also better (93.6%), but it 
suggests that eight patients (6.4%) secrete detectable amounts 
of serum HER2. Overall these results demonstrate that serum 
HER2 is not a reliable determinant of the HER2 status of a     
tumor. It is likely that the secretion of ECD is influenced by 
factors such as tumor vascularization or the activity of TMPs. 
A number of studies found that serum HER2 levels is likely to 
be markedly influenced by tumor load/size. The utility of serum 
HER2 levels at baseline and during therapy as a potential 
marker of tumor response or progression is currently a matter 
of debate. In a study of 43 patients with metastatic breast can-
cer, elevated pretreatment serum levels of ECD were associated 
with poor clinical responsiveness to hormone therapy and 
chemotherapy [21,22]. Conversely, in another study of patients 
with HER2-positive metastatic breast cancer, 19 of 55 patients 
with elevated serum HER2 levels at baseline demonstrated sig-
nificantly higher response rates to trastuzumab-based treat-
ments [23-25]. Trastuzumab reduces the cleavage of serum 
HER2 by metalloproteases, thus reducing serum HER2, and   
it has been suggested that early changes in serum HER2 may 
predict both subsequent responses to trastuzumab and pro-
gression-free survival [26-28]. It was also suggested, following 
a study of 210 patients, that increases in domains: a cytoplasmic 
domain and a transmembrane of serum HER2 might indicate 
disease recurrence or metastasis after adjuvant treatment [29, ChangesinSerumHER2LevelsduringFollow-upPeriod 77
http://dx.doi.org/10.4048/jbc.2012.15.1.71  http://ejbc.kr
30]. It is important to note that the patient numbers in most of 
these trials were relatively small and, therefore, provide insub-
stantial evidence on which to base treatment decisions. Also 
the preliminary results we present were obtained from a rela-
tively small number of patients. So this issue should be clarified 
with larger prospective studies. Also, we did not do biopsies, so 
we were not able to determine whether a change in the level of 
serum HER2 took place in the metastasis of patients with a high 
level serum HER2 and a negative tissue HER2 status. Accord-
ing to our study, ER-negativity was associated with high serum 
HER2. And AJCC N0 stage was associated with low serum 
HER2. But serum HER2 was not associated with advanced 
staging. So serum HER2 can’t be thought of as an advanced 
AJCC TNM stage. And serum HER2 changes with more than 
20% elevation were associated with advanced AJCC TNM stag-
ing. And there is a significant association between serum HER2 
and 5-year DFS not including the OS rate. And there is a signif-
icant association between serum HER2 level changes of more 
than 20% and 5-year DFS rate, including the OS rate. Tumor 
size was also an important factor affecting 5-year DFS rate. But 
there are several limitations to our study. The primary limita-
tion of our study is the small sample size; as a consequence, it 
had low statistical power to detect associations. In addition, 
we had limited evidence of an association between changes in 
serum HER2 levels and survival rate. To the best of our knowl-
edge, this is one of a few studies to show an association between 
changes in serum HER2 levels after adjuvant chemotherapy 
and survival rate. To more powerfully demonstrate the results 
observed in our study, further prospective functional studies 
are needed to validate our findings.
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